Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone

Berry, Donna L.; Moinpour, Carol M.; Jiang, Caroline S.; Ankerst, Donna P.; Petrylak, Daniel P.; Vinson, Lynne V.; Lara, Primo N.; Jones, Sharon; Taplin, Mary Ellen; Burch, Patrick A.; Hussain, Maha; Crawford, E. David

doi:10.1200/jco.2005.04.8207

Cited by 76 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In SWOG 99-16, palliation of bone pain and global quality of life were not significantly different between the 2 treatment arms. 34 In contrast, pain response rates in the docetaxel group were 35% and 31% for every-3-week and weekly docetaxel, respectively, significantly better than the 22% observed with mitoxantrone. Both pain response and PSA declines correlated with survival in patients treated on the TAX327 study.…”

Section: Single-agent Docetaxel Therapymentioning

confidence: 68%

Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel

Cheetham

Petrylak²

2013

The Cancer Journal

Self Cite

View full text Add to dashboard Cite

Microtubules are dynamic filamentous cytoskeletal proteins that are responsible for cellular integrity and architecture, mitosis, intracellular transport, cell signaling, and gene expression. Tubulin exists in the cell as dimers of α and β subunits, which complexes with a variety of regulatory proteins. There is a dynamic equilibrium between free and polymerized tubulin causing a state called "dynamic instability," which is a target of anticancer drugs, which inhibit tubulin through polymerization (taxanes, epothilones) or depolymerization (vinca alkaloids). Docetaxel-based therapy was the first such treatment to demonstrate a survival benefit in men with castration-resistant prostate cancer. Cabazitaxel, an antitubulin agent, which demonstrates activity in multidrug- and docetaxel-resistant cancer cell lines, demonstrates a survival benefit over mitoxantrone and prednisone in patients who have failed docetaxel-based chemotherapy. This article reviews the use of antitubulin agents in patients with castration-resistant prostate cancer.

show abstract

Section: Single-agent Docetaxel Therapymentioning

confidence: 68%

Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel

Cheetham

Petrylak²

2013

The Cancer Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other clinically important endpoints were redefined, like the evaluation of pain intensity and other parameters, such as the use of analgesic drugs, the performance status and quality of life [15] . Several studies conducted in patients with mCRPC symptoms have demonstrated that mitoxantrone or docetaxel in combination with corticosteroids could improve symptoms but they were not able to significantly increase the survival benefit [16,17] .…”

Section: Introductionmentioning

confidence: 99%

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

Cicero

Luca²,

Dorangricchia³

et al. 2016

Oncology

View full text Add to dashboard Cite

Purpose: The present study aims to evaluate the efficacy of cabazitaxel in combination with prednisone treatment in Italian patients affected by hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel plus prednisone. Methods: Thirty patients with mCRPC were enrolled between June 2013 and January 2016 (the last follow-up was in January 2016). Cabazitaxel was used according to the summary of product characteristics and administered at a dose of 25 mg/m² every 3 weeks plus oral prednisone at a dose of 5-mg tablets twice a day continuously. The reduction in serum prostate-specific antigen (PSA) was the primary endpoint while reducing pain, safety, progression-free survival, response rate and overall survival (OS) were secondary endpoints. Results: Cabazitaxel was well tolerated, showing a manageable toxicity profile, associated with a modest objective response rate and a good reduction in PSA levels. Only 12 patients (40%) had a partial response, 10 patients (33%) showed stabilization of disease and 8 (27%) experienced disease progression. The median OS was 14.8 months (95% CI: 11.6-19.8). The linear regression analysis revealed that PSA response was an important predictor of OS, showing a positive correlation with OS (β = 0.377, p < 0.01). Conclusions: Three-week treatment with cabazitaxel was found to be valid and was a well-tolerated treatment option for patients with mCRPC after a first-line docetaxel treatment.

show abstract

“…Over the past few decades, systemic cytotoxic therapies have demonstrated improvements in pain and quality of life among patients with advanced cancers in many trials [3,50,63]. In a recent clinical trial in patients with advanced prostate cancer (N=674), mitoxantrone plus prednisone or docetaxel plus estramustine both palliated pain to a similar extent (24% and 21% of patients in each group, respectively) [9]. In another study, in patients with advanced solid tumors (N=146), chemotherapy produced pain relief compared with baseline based on questions from the EORTC QLQ-C30 [5].…”

Section: Bone Painmentioning

confidence: 94%

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

Costa

Badı́a²,

Chow

et al. 2008

Support Care Cancer

180

133

View full text Add to dashboard Cite

Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.

show abstract

Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone

Abstract: DE had superior clinical efficacy (overall survival, time-to-progression, and prostate-specific antigen declines) with similar global QOL and pain palliation in the MP arm.

Cited by 76 publications

References 26 publications

Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel

Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

Contact Info

Product

Resources

About